Skip to main content

Scleroderma/Raynauds

First Look at COVID-19 Global Rheumatology Alliance Registry

Jun 01, 2020

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect

Read Article

Systemic Sclerosis Future Therapies and Outcome Measures

May 19, 2020

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,

Read Article

RheumNow Podcast – The Beat Goes On (5.8.20)

May 07, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article

Lenabasum Encouraging in Systemic Sclerosis

Apr 30, 2020

The oral cannabinoid receptor type 2 (CB2) agonist lenabasum showed promising results for systemic sclerosis (SSc) in a phase II study.

At week 16, the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) increased to 0.33 among

Read Article

RheumNow Podcast – In Times of Trouble (4.24.20)

Apr 24, 2020

Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com

Read Article

Treatment of Statin-induced anti-HMGCR myopathy

Jan 10, 2020

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of

Read Article

CRP in SSc: Identifying a Severe Phenotype

Dec 12, 2019

Patients with systemic sclerosis (SSc) who have persistent inflammation -- characterized by consistently elevated levels of C-reactive protein (CRP) -- have more severe disease and worse outcomes, a retrospective study confirmed.

In a cohort of 131 patients, those with the inflammatory

Read Article

RheumNow Podcast – Believe in Vitamin D or Rituximab? (9.20.19)

Sep 20, 2019

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

RheumNow Podcast – The End of Arthritis (9.13.19)

Sep 13, 2019

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Sep 10, 2019

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Read Article

Nintedanib FDA Approved for Scleroderma Lung Disease

Sep 09, 2019

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.

ILD as a complication of SSc may lead to progressive loss of

Read Article

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Aug 02, 2019

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com:
MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.

Read Article

Abatacept Disappoints in Systemic Sclerosis

Jul 29, 2019

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

A total of 169 dsSSc

Read Article

RheumNow Podcast – FDA Hyperactivity (7.26.19)

Jul 26, 2019

Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com

Read Article

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

Jul 25, 2019

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.

Read Article

EULAR 2019 Report – Day 2

Jul 02, 2019

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day two at

Read Article

DMARD Success in Myositis-Related Interstitial Lung Disease

Jun 26, 2019

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil

Read Article

EULAR 2019 Report – Day 2

Jun 13, 2019

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

Read Article

RheumNow Podcast – Rituximab Monitoring (5.31.19)

May 31, 2019

Dr. Jack Cush presents the news and best of rheumatology and medicine from the past week on RheumNow.com

Read Article

RheumNow Podcast – Medical Selfies (5.24.19)

May 24, 2019

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com

Read Article

Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease

May 21, 2019

The NEJM reports a randomized placebo controlled trial of nintedanib, a tyrosine kinase inhibitor, in systemic sclerosis patients with interstitial lung disease (ILD) resulted in less pulmonary decline, but had no effect on other features of systemic sclerosis. 

Read Article

RheumNow Podcast – Take it Back Jack! (4.26.19)

Apr 26, 2019

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

RheumNow Podcast – You Owe Me a DEXA (3.15.19)

Mar 15, 2019

Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.

Read Article

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

Mar 12, 2019

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based

Read Article

Mortality and Hospitalization with Pulmonary Hypertension in Systemic Sclerosis

Feb 14, 2019

PHAROS is a prospective cohort studying the natural history of pulmonary hypertension (PH) in systemic sclerosis (SSc). They have shown that risk factors for poor outcomes in this cohort included male sex, DLCO < 50%, exercise oxygen desaturation, and pericardial effusions. 

They

Read Article
×